@entity60184 is an orally available multi-targeted @entity669 kinase inhibitor with anti-angiogenic and antitumor activity. To get more insight into the disposition of @entity60184 , a mass balance study was performed in @entity1 with advanced solid @entity5 . A single oral 24  mg (100   Ci) dose of (14)C-lenvatinib was administered to six @entity1 , followed by collection of blood, plasma, urine and feces for 7 to 10  days. The collected material was analyzed for total radioactivity, unchanged @entity60184 and selected metabolites. The safety and antitumor effect of a daily oral dose of 24  mg non-labeled @entity60184 were assessed in the extension phase of the study. Peak plasma concentrations of @entity60184 and total radioactivity were reached 1.6 and 1.4  h after administration, respectively, and their terminal phase half-lifes were 34.5 and 17.8  h, respectively. Unchanged @entity60184 systemic exposure accounted for 60  % of the total radioactivity in plasma. Peak concentrations of the analyzed metabolite were over 700-fold lower than the peak plasma concentration of @entity60184 . Ten days after the initial dose, the geometric mean (   CV) recovery of administered dose was 89  %   10  %, with 64  %   11  % recovered in feces and 25  %   18  % in urine. Unchanged @entity60184 in urine and feces accounted for 2.5  %   68  % of the administered dose, indicating a major role of metabolism in the elimination of @entity60184 . In conclusion, @entity60184 is rapidly absorbed and extensively metabolized, with subsequent excretion in urine and, more predominantly, in feces. Additionally, @entity60184 showed acceptable safety and preliminary antitumor activity.

Pharmacokinetics and excretion of (14)C-lenvatinib in @entity1 with advanced solid XXXX or lymphomas.

@entity1 :: ('9606', 'Species') :: ['patients'] @entity669 :: ('CHEBI:18186', 'Chemical') :: ['tyrosine'] @entity60184 :: ('MESH:C531958', 'Chemical') :: ['Lenvatinib', 'lenvatinib'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumors']
@entity5 :: (MESH:D009369,Disease) :: ['tumors']
